Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 2.51 | 3.29% | 0.08 |
Earnings due: Mar 19
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 50 DMA | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Fell Below 50 DMA | Bearish | 3.29% | |
Bollinger Band Squeeze | Range Contraction | 3.29% | |
50 DMA Support | Bullish | 0.56% | |
Bollinger Band Squeeze | Range Contraction | 0.56% | |
20 DMA Resistance | Bearish | -3.09% | |
Crossed Above 50 DMA | Bullish | -3.09% | |
Bollinger Band Squeeze | Range Contraction | -3.09% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
60 Minute Opening Range Breakout | about 13 hours ago |
Gap Up Closed | about 15 hours ago |
Gap Up Partially Closed | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 03/19/2024
Cyclacel Pharmaceuticals, Inc. Description
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Cyclacel Cell Cycle Cyclin Dependent Kinase Dna Synthesis Human Cancers PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.2 |
52 Week Low | 2.0 |
Average Volume | 176,787 |
200-Day Moving Average | 5.87 |
50-Day Moving Average | 2.50 |
20-Day Moving Average | 2.62 |
10-Day Moving Average | 2.51 |
Average True Range | 0.24 |
RSI (14) | 48.19 |
ADX | 17.01 |
+DI | 19.11 |
-DI | 16.58 |
Chandelier Exit (Long, 3 ATRs) | 2.37 |
Chandelier Exit (Short, 3 ATRs) | 3.01 |
Upper Bollinger Bands | 2.91 |
Lower Bollinger Band | 2.33 |
Percent B (%b) | 0.31 |
BandWidth | 21.99 |
MACD Line | -0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0151 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.80 | ||||
Resistance 3 (R3) | 2.79 | 2.69 | 2.75 | ||
Resistance 2 (R2) | 2.69 | 2.62 | 2.69 | 2.73 | |
Resistance 1 (R1) | 2.60 | 2.57 | 2.65 | 2.61 | 2.72 |
Pivot Point | 2.50 | 2.50 | 2.52 | 2.50 | 2.50 |
Support 1 (S1) | 2.41 | 2.43 | 2.46 | 2.42 | 2.30 |
Support 2 (S2) | 2.31 | 2.38 | 2.31 | 2.29 | |
Support 3 (S3) | 2.22 | 2.31 | 2.27 | ||
Support 4 (S4) | 2.23 |